Discover
ALNY
Alnylam Pharmaceuticals, Inc.
301.67
1 x 305.63
1 x 294.46
bid
ask
+
0.64
0.21%
1 @ 04:59 AM
307.48 +5.81 (1.93%)
| Ytd | -24.14% | |
| 1y | -6.33% |
301.50
day range
309.27
273.11
52 week range
495.55
| Open | 304.54 | Prev Close | 301.03 | Low | 301.50 | High | 309.27 | Mkt Cap | 40.28B |
| Vol | 1.04M | Avg Vol | 1.14M | EPS | 3.98 | P/E | 75.80 | Forward P/E | 22.22 |
| Beta | 0.27 | Short Ratio | 5.14 | Inst. Own | 102.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 295.74 | 200-d Avg | 367.67 | 1yr Est | 434.72 |
| Income Statement | |||
| Total Revenue | 1.17B | ||
| Revenues (USD) | 1.17B | ||
| Cost of Revenue | 211.12M | ||
| Gross Profit | 956.05M | ||
| Operating Expenses | 687.42M | ||
| Research and Development Expense | 364.87M | ||
| Selling, General and Administrative Expense | 322.55M | ||
| Operating Income | 268.64M | ||
| Interest Expense | 69.29M | ||
| Income Tax Expense | 15.66M | ||
| Net Income | 205.99M | ||
| Net Income Common Stock | 205.99M | ||
| Net Income Common Stock (USD) | 205.99M | ||
| Consolidated Income | 205.99M | ||
| Earnings per Basic Share | 1.55 | ||
| Earnings per Basic Share (USD) | 1.55 | ||
| Earnings per Diluted Share | 1.51 | ||
| Earning Before Interest & Taxes (EBIT) | 290.94M | ||
| Earning Before Interest & Taxes (USD) | 290.94M | ||
| Weighted Average Shares | 132.89M | ||
| Weighted Average Shares Diluted | 138.23M | ||
| Balance Sheet | |||
| Cash and Equivalents | 1.71B | ||
| Cash and Equivalents (USD) | 1.71B | ||
| Investments | 1.32B | ||
| Investments Current | 1.30B | ||
| Investments Non-Current | 22.17M | ||
| Trade and Non-Trade Receivables | 883.96M | ||
| Current Assets | 4.22B | ||
| Property, Plant & Equipment Net | 707.56M | ||
| Total Assets | 5.13B | ||
| Debt Current | 273.15M | ||
| Total Debt | 2.97B | ||
| Current Liabilities | 1.35B | ||
| Debt Non-Current | 2.70B | ||
| Total Liabilities | 4.05B | ||
| Accumulated Retained Earnings (Deficit) | -6.50B | ||
| Accumulated Other Comprehensive Income | -24.89M | ||
| Shareholders Equity | 1.08B | ||
| Shareholders Equity (USD) | 1.08B | ||
| Assets Non-Current | 910.24M | ||
| Total Debt (USD) | 2.97B | ||
| Deferred Revenue | 3.21M | ||
| Inventory | 84.03M | ||
| Liabilities Non-Current | 2.70B | ||
| Trade and Non-Trade Payables | 126.63M | ||
| Tax Assets | 116.96M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 13.55M | ||
| Net Cash Flow from Financing | 15.71M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 53.61M | ||
| Capital Expenditure | -21.83M | ||
| Issuance (Purchase) of Equity Shares | 13.16M | ||
| Issuance (Repayment) of Debt Securities | 2.57M | ||
| Net Cash Flow from Investing | -25.54M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -3.71M | ||
| Net Cash Flow from Operations | 70.50M | ||
| Effect of Exchange Rate Changes on Cash | -7.06M | ||
| Share Based Compensation | 70.15M | ||